MMP9 and cancer: The matriptase-activated PAR-2/PI3K/Akt/MMP9 signaling axis results in the cleavage of E-cadherin and the release of soluble E-cadherin, disrupting cell–cell interactions and facilitating peritoneal dissemination in cancer cells [40].